AUSTRALASIA

After Africa, Aspen Australasia is the second largest revenue contributor to Regional Brands, with a comprehensive portfolio of medicines comprising Regional and Global Brands, including prescription and OTC products, as well as Sterile Focus Brands. There is also a manufacturing site in Australia, which produces FDF and undertakes third-party manufacturing.

Key Countries

Australia
New Zealand

KEY BRANDS

Brand		Therapeutic category
Circadin		Hormonal hypnotic sedative
Eltroxin		Thyroid hormone replacement
Maltofer		Iron supplement
Marcaine		Regional and spinal anaesthetic
Xylocaine		Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

563

June 2022

538

June 2021

STATISTICS

Number of products launched:

8

(2021: 2)

Number of product recalls:

Nil

(2021: Nil)

Average staff turnover:

12%

(2021: 8%)

Number of work-related fatalities:

Nil

(2021: Nil)

Sales representatives:

83

(2021: 74)

Revenue	2022 R’million	2021 (CER) R’million	Change %
Commercial Pharmaceuticals	5 107	4 680	9
Regional Brands	4 464	3 955	13
Sterile Focus Brands	643	725	(11)
Manufacturing – FDF	596	532	12
Total	5 703	5 212	9

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.

The Australia and New Zealand OTC market was valued at AUD4,5 billion in June 2022 and grew 12,9% driven by recovery of various therapeutic segments specifically the Cough/Cold/Flu and related segments as a result of stay-at-home COVID-19 treatments and severe cold and flu season.
The total pharmaceutical segment excluding the grocery channel grew 9,2% June 2022.

Source: IQVIA June 2022